CCL2 and type 2 diabetes mellitus: A study has analyzed how plasma DPP-4 activity and levels of soluble DPP-4 correlate with inflammatory markers (C-reactive protein [CRP], IL-6, TNF-α, and monocyte chemoattractant protein-1 [MCP-1]) in a subset of patients with T2DM treated with sitagliptin for 12 months as part of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS, 26).